

Date: 27/02/2025

To

BSE Limited
Dept. of Corporate Services,
Floor 25, PJ Towers,
Dalal Street, Mumbai-400001

Scrip Code: 526445

Dear Sir/Madam,

Sub: Outcome of Board Meeting under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to our intimations submitted on 10/02/2025, 14/02/2025 and 26/02/2025 on Board meeting, and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that at the meeting of Board of Directors held today i.e., on Friday, February 27, 2025, the Directors have inter-alia, considered:

- i. Unaudited Financial Results (Standalone and Consolidated) with the Limited Review Report for the quarter and Nine months ended December 31, 2024 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The statutory auditors have reviewed the financial results. (Results are provided as Annexure-I). The necessary arrangements are in place to publish the unaudited financial results in the newspapers.
- ii. Pursuant to the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, a Disclosure on Integrated filing (financial) the quarter ended December 31, 2024 has been annexed (Annexure-II).

The meeting commenced at 05:00 p.m. and concluded at 07:15 p.m.

We request you to kindly take the same on your records.

Thanking you,

Yours faithfully,

For Indrayani Biotech Limited

V Santhanakrishnan
Company Secretary and Compliance Officer

Encl.: as above



Limited Review Report on consolidated unaudited quarterly to date financial results of the company Pursuant to the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015

To
The Board of Directors
Indrayani Biotech Limited

1. We have reviewed the accompanying Statement of Consolidated Financial Results of Indrayani Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income / loss of its associates for the quarter ended **31st December, 2024** and for the period from 1st October 2024 to 31st December 2024 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31st December, 2023 and corresponding period from 1st October 2023 to 31st December 2023 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to audit/review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our review of such consolidated financial statements.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Basis for Qualified Review

4. The consolidated financial results of Indrayani Biotech Limited for the quarter and nine months ended December 31, 2024, do not include the financial results of our material subsidiary, Dindigul Farm Product Limited, as the financial statements of the said entity are not received. However, the financial results for the first six months of the financial year include the results of this subsidiary. Since its financials of said material subsidiary have not been considered for the quarter ended December 31, 2024, the consolidated figures for the quarter and nine months ended December 31, 2024 are not comparable with the corresponding previous quarters / nine months period in the above financial results which are reported inclusive of financials of said material subsidiary.



5. The Statement includes the results of the entities mentioned in the Annexure – I, is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended;
6. Based on our review conducted and procedures performed as stated in paragraph above except for the effects of the matters described in paragraphs 4 and based on the consideration of the reports of the management referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the financial statement / financial information of **6 Subsidiaries and 3 step down subsidiaries** included in the consolidated unaudited financial results, whose interim financial information for the Period ended 31st December, 2024 reflects total revenues of ₹ **2,488.15 Lakhs**, total comprehensive profit / (loss) of ₹ **7.2 Lakhs** for the period ended on that date as considered in the consolidated financial results.

This financial information have been reviewed by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the Management and the procedures performed by us as stated in paragraph mentioned above.

for Venkatesh & Co

Chartered Accountants

FRN : 004636S

HRISHIK Digitally signed
by HRISHIKESH
ESH Date: 2025.02.27
18:37:34 +05'30'

CA Hrishikesh D

Partner

M No : 272865

UDIN: **25272865BMLKXV5315**

Chennai, 27th February 2024


Annexure I to the Audit Report

List of subsidiaries, associates and joint ventures included in the consolidated Quarterly Unaudited financial results:

S. No.	Name of the entity	Relationship
1	IBL Health Care Limited	Subsidiary
2	HSL Agri Solutions Limited	Subsidiary
3	HSL Prime Properties Private Limited	Subsidiary
4	Healthway India Private Limited	Step Down Subsidiary
5	IBL Thiruvannamalai LLP	Step Down Subsidiary
6	Dindigul Farm Product Limited*	Subsidiary
7	Matrix Boilers Private Limited	Subsidiary
8	IBL Investments Limited	Subsidiary
9	IBL Social Foundation	Subsidiary
10	Kniss Laboratories Private Limited	Step Down Subsidiary

***As mentioned in the Paragraph 4, The Unaudited Consolidated Results does not include the Results of M/s. Dindigul Farm Product Limited for the Quarter Ended 31st December 2024**

M/s. INDRAYANI BIOTECH LIMITED							
CIN : L40100TN1992PLC129301							
#32 & 33 Block: I, 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.							
STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024							
Rs in Lakhs							
S No	Particulars	CONSOLIDATED					
		Quarter Ended			9 months ending		Year Ended
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
I	Revenue from Operations	1,731.82	3,081.31	3,909.27	7,965.91	12,184.54	16,622.56
II	Other Income	0.38	30.13	8.24	34.94	18.16	121.49
III	Total Income	1,732.21	3,111.44	3,917.51	8,000.86	12,202.70	16,744.06
IV	Expenses						
	Cost of Materials consumed	1,004.77	1,709.42	2,444.49	4,381.19	7,712.03	9,713.25
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	8.64	-222.25		-122.27		
	Employee Benefit Expense	341.79	513.94	497.31	1,427.68	1,546.81	2,392.94
	Finance Cost	102.60	141.60	140.71	469.06	436.95	988.25
	Depreciation and amortization expense	146.16	279.46	103.43	508.36	284.10	380.06
	Other expenses	84.96	569.44	623.35	1,079.25	1,598.66	2,172.11
	Total Expenses	1,688.93	2,991.61	3,809.29	7,743.29	11,578.54	15,646.62
V	Profit / (loss) before exceptional items and tax	43.28	119.84	108.23	257.57	624.16	1,097.44
VI	Exceptional Items						
	Add : Share of profit In Associates						
VII	Profit / (loss) before tax	43.28	119.84	108.23	257.57	624.16	1,097.44
VIII	Current Tax Expense	8.13	-1.85	-	15.73	-	61.85
IX	Deferred Tax Expense						-6.66
X	Profit (Loss) for the period from continuing operations (VII-VIII)	35.14	121.69	108.23	241.85	624.16	1,042.25
X	Profit (Loss) for the period from discontinued operations						
XI	Profit (Loss) for the period (VII-VIII)						
XII	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss		-				-
	(ii) Income tax relating to items that will not be reclassified to profit or loss		-				-
	B (i) Items that will be reclassified to profit or loss		-				-
	(ii) Income tax relating to items that will be reclassified to profit or loss		-				-
XIII	Total Comprehensive income for the period attributable to	35.14	121.69	108.23	241.85	624.16	1,042.25
	Comprehensive income for the period attributable to owners of parent	23.86	61.20	98.05	128.97	389.89	636.49
	Total comprehensive income for the period attributable to Non-controlling Interests	11.29	60.48	10.19	112.89	234.27	405.79
	Paid-up equity share capital (Face value Rs.10 each)	4,553.63	4,553.63	4,553.63	4,553.63	4,553.63	4,553.63
XX	Earnings Per Share:(*not annualized)						
	(1) Basic	0.05*	0.13*	0.22*	0.10*	0.86*	1.40
	(2) Diluted	0.05*	0.13*	0.22*	0.10*	0.86*	1.40



For INDRAYANI BIOTECH LIMITED

[Signature]
Director

Notes:

1. The above consolidated financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 27th February 2025 and have been subjected to review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

2. The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com).


3. The consolidated financial results of Indrayani Biotech Limited (IBL) for the quarter ended December 31, 2024, does not include the financial results of our material subsidiary, Dindigul Farm Product Limited (DFPL), as the financial results of the said entity for the quarter ended December 31, 2024, have not been received. The management of DFPL has requested additional time to share the said financial results. However, the Audit Committee of IBL has taken note of this request and has advised the Board of Directors to proceed with the adoption of the unaudited financial results of the Company for the quarter ended December 31, 2024, excluding DFPL's financials for the quarter. In view of the above, the unaudited consolidated financial results of IBL, does not include financial figures of DFPL for the quarter.

4. Previous period figures have been regrouped wherever necessary.

5. There is no investor complaint received during the quarter.

Date: 27.02.2025

Place: Chennai



For Indrayani Biotech Limited


G Swaminathan
Whole-Time Director
(DIN:02481041)



Limited Review Report on Quarterly Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors,

Indrayani Biotech Limited

We have reviewed the accompanying statement of unaudited standalone financial results of **Indrayani Biotech Limited** ('the Company') for the quarter ended 31st December 2024. This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for Venkatesh & Co

Chartered Accountants

FRN : 004636S

HRISHIK Digitally signed
by HRISHIKESH
ESH Date: 2025.02.27
18:36:35 +05'30'

CA Hrishikesh D

Partner

M No : 272865

UDIN: **25272865BMLKXU2954**

Chennai, 27th February 2025

M/s. INDRAYANI BIOTECH LIMITED

CIN : L40100TN1992PLC129301

#32 & 33 Block: I, 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.

STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st December, 2024

Rs in Lakhs

S No	Particulars	STANDALONE					
		Quarter Ended			Nine Months ending		Year Ended
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
I	Revenue from Operations	818.82	950.69	1,369.22	2,848.60	4,652.41	6,232.34
II	Other Income	66.21	89.38	8.17	258.19	17.30	361.88
III	Total Income	885.03	1,040.07	1,377.39	3,106.79	4,669.71	6,594.22
IV	Expenses						
	Cost of Materials consumed	334.29	379.96	772.02	1,198.77	2,753.00	3,515.38
	Employee Benefit Expense	269.37	320.38	326.53	993.33	1,078.63	1,569.08
	Finance Cost	152.49	188.52	77.97	492.64	235.51	482.76
	Depreciation and amortization expense	32.34	31.76	36.71	96.08	109.30	144.76
	Other expenses	82.36	106.29	137.79	281.58	354.74	581.31
	Total Expenses	870.85	1,026.91	1,351.02	3,062.40	4,531.18	6,293.29
V	Profit / (loss) before exceptional items and tax	14.18	13.16	26.37	44.39	138.53	300.91
VI	Exceptional Items						
	Add : Share of profit In Associates						
VII	Profit / (loss) before tax	14.18	13.16	26.37	44.39	138.53	300.91
VIII	Current Tax Expense	3.57	3.27	-	11.17	-	54.17
IX	Deferred Tax Expense	-	-	-	-	-	101.00
X	Profit (Loss) for the period from continuing operations (VII-VIII)	10.61	9.89	26.37	33.22	138.53	145.74
X	Profit (Loss) for the period from discontinued operations						
XI	Profit (Loss) for the period (VII-VIII)						
XII	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XIII	Total Comprehensive Income for the period (XII+XI)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	10.61	9.89	26.37	33.22	138.53	145.74
XIV	Paid-up equity share capital (Face value Rs.10 each)	4,553.63	4,553.63	4,553.63	4,553.63	3,422.72	4,553.63
XX	Earnings Per Share:(*not annualized)						
	(1) Basic	0.02*	0.02*	0.06*	0.07*	0.40*	0.37
	(2) Diluted	0.02*	0.02*	0.06*	0.07*	0.40*	0.37

Notes:

1. The above Standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 27th February 2025 and have been subjected to review by the Statutory Auditors of the company. The above results have been prepared in accordance with the Indian Accounting Standards-(Ind AS) as prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

2. The financial results are being forwarded to the Bombay Stock Exchange & also available on the company website (www.indrayani.com)

3. Previous period figures have been regrouped wherever necessary.

4. There is no investor complaint received during the quarter.

Date: 27-02-2025

Place: Chennai

For Indrayani Biotech Limited

G Swaminathan

Whole-Time Director (DIN:02481041)



Annexure-II

Disclosure on Integrated filing (financial) the quarter ended December 31, 2024 pursuant to the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024

QUARTERLY INTEGRATED FILING (FINANCIAL)

A. Financial Results

Unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31, 2024 along with the Limited Review Report of the Statutory Auditors, attached as Annexure-I.

B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.

Not applicable

C. Format for disclosing outstanding default on loans and debt securities

Not applicable

D. Format for disclosure of related party transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Not Applicable

E. Statement on impact of audit qualifications (for audit report with modified opinion) along-with annual audited financial results - (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter)

Not Applicable